Related Experiment Videos
Monoaminergic mechanisms and experimental cataplexy
Annals of Neurology
|October 1, 1981
Summary
Norepinephrine (NE) and serotonin (5-HT) systems influence narcolepsy. Drugs blocking NE uptake, like nisoxetine, effectively reduced cataplexy in dogs, suggesting a key role for NE in this condition.
Area of Science:
- Neuroscience
- Pharmacology
- Sleep Medicine
Background:
- Narcolepsy is a neurological disorder characterized by excessive daytime sleepiness and cataplexy.
- Monoamine systems, including norepinephrine (NE) and serotonin (5-HT), are implicated in the pathophysiology of narcolepsy.
- Understanding the neurochemical underpinnings of cataplexy is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the effects of modulating monoamine systems on cataplexy in a canine model of narcolepsy.
- To determine the relative contributions of norepinephrine and serotonin pathways to cataplexy.
- To explore potential therapeutic targets for narcolepsy.
Main Methods:
- Utilized a canine model of narcolepsy with eight severely affected dogs.
- Quantified cataplexy using the food-elicited cataplexy test.
- Administered various pharmacological agents targeting monoamine systems, including NE and 5-HT reuptake inhibitors, tricyclic antidepressants, and receptor blockers.
Main Results:
- Nisoxetine (NE uptake blocker) and fluoxetine (5-HT uptake blocker) significantly suppressed cataplexy, with NE inhibition being more potent.
- Tricyclic antidepressants (protriptyline, amitriptyline, chlorimipramine) also reduced cataplexy.
- Methylphenidate, clonidine, and pimozide showed cataplexy-suppressing effects, while propranolol, gamma-hydroxybutyrate, clorgyline, and pargyline had minimal impact.
Conclusions:
- Inhibition of norepinephrine uptake is a more effective strategy for suppressing experimental cataplexy than serotonin uptake inhibition.
- Many drugs suppressing cataplexy also suppress REM sleep, suggesting a link between these phenomena.
- Aminergic-cholinergic interactions may play a role in the mechanisms underlying cataplexy, as evidenced by physostigmine reversing nisoxetine-induced suppression.